These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29931506)

  • 1. There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study.
    Kinoshita T; Shimoda M; Sanada J; Fushimi Y; Hirata Y; Irie S; Obata A; Kimura T; Hirukawa H; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Ther; 2018 Aug; 9(4):1569-1580. PubMed ID: 29931506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial.
    Baba Y; Ishibashi R; Takasaki A; Ito C; Watanabe A; Tokita M; Meguro M; Harama T; Hirayama K; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 May; 12(5):1415-1427. PubMed ID: 33738773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.
    Wang Y; Hu X; Liu X; Wang Z
    Ther Clin Risk Manag; 2016; 12():1113-31. PubMed ID: 27486328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
    Hayashi A; Takano K; Kawai S; Shichiri M
    Endocr J; 2016; 63(2):187-91. PubMed ID: 26549210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan.
    Ishibashi R; Baba Y; Kakinuma K; Takasaki A; Hiraga C; Harama T; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 Jan; 12(1):453-460. PubMed ID: 33237553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus.
    Usui M; Tanaka M; Takahashi H
    J Clin Transl Endocrinol; 2020 Sep; 21():100233. PubMed ID: 32904185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Tanaka A; Node K
    J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
    Ito H; Shinozaki M; Nishio S; Abe M
    Expert Opin Pharmacother; 2016 Oct; 17(15):2073-84. PubMed ID: 27592508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice.
    Jurczak MJ; Saini S; Ioja S; Costa DK; Udeh N; Zhao X; Whaley JM; Kibbey RG
    Islets; 2018; 10(5):181-189. PubMed ID: 30118626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
    Washburn WN; Poucher SM
    Expert Opin Investig Drugs; 2013 Apr; 22(4):463-86. PubMed ID: 23452053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.